

1 AN ACT relating to prior authorizations.

2 ***Be it enacted by the General Assembly of the Commonwealth of Kentucky:***

3 ➔Section 1. KRS 304.17A-611 is amended to read as follows:

4 **(1)** A utilization review decision shall not retrospectively deny coverage for health care  
5 services provided to a covered person when prior approval has been obtained from  
6 the insurer or its designee for those services, unless the approval was based upon  
7 fraudulent, materially inaccurate, or misrepresented information submitted by the  
8 covered person, authorized person, or the provider.

9 **(2) *An insurer shall not require or conduct a prospective or concurrent review for a***  
10 ***prescription drug that:***

11 **(a) *Is used in the treatment of opioid use disorder; and***

12 **(b) *Contains Methadone, Buprenorphine, or Naltrexone.***

13 ➔Section 2. KRS 205.536 (Effective January 1, 2019) is amended to read as  
14 follows:

15 (1) A Medicaid managed care organization shall have a utilization review plan, as  
16 defined in KRS 304.17A-600, that meets the requirements established in 42 C.F.R.  
17 pts. 431, 438, and 456. If the Medicaid managed care organization utilizes a private  
18 review agent, as defined in KRS 304.17A-600, the agent shall comply with all  
19 applicable requirements of KRS 304.17A-600 to 304.17A-633.

20 (2) In conducting utilization reviews for Medicaid benefits, each Medicaid managed  
21 care organization shall use the medical necessity criteria selected by the Department  
22 of Insurance pursuant to KRS 304.38-240, for making determinations of medical  
23 necessity and clinical appropriateness pursuant to the utilization review plan  
24 required by subsection (1) of this section.

25 **(3) *The Department for Medicaid Services or any managed care organization***  
26 ***contracted to provide Medicaid benefits pursuant to KRS Chapter 205 shall not***  
27 ***require or conduct a prospective or concurrent review, as defined in KRS***

- 1        **304.17A-600, for a prescription drug that:**
- 2        **(a) Is used in the treatment of opioid use disorder; and**
- 3        **(b) Contains Methadone, Buprenorphine, or Naltrexone.**
- 4        ➔Section 3. This Act takes effect January 1, 2020.